Detection of matrix metalloproteinases (MMP), tissue inhibitor of metalloproteinase-2, urokinase and plasminogen activator inhibitor-1 within matrigel and growth factor-reduced Matrigel basement membrane

Tumori

Volumn 89, Issue 4, 2003, Pages 421-425

  Gillette, Karin M ^a   Forbes, Katie ^a   Sehgal, Inder ^a,b  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

MMP; PAI 1; TIMP; uPA

Indexed keywords

GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MATRIGEL; MATRILYSIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PROSTATE CANCER;

EID: 0142041921     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900415     Document Type: Article

References (21)

1. BD biosciences product specification sheet for Matrigel basement membrane matrix, release date: 2/15/02.
2. Vukicevic S, Kleinman HK, Luyten FP, Roberts A, Roche NS, Reddi AH: Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res, 202: 1-8, 1992.
3. BD biosciences product specification sheet for growth factor reduced matrigel matrix, release date: 10/19/01.
4. Taub M, Wang Y, Szczesny TM, Kleinman, HK: Epidermal growth factor or transforming growth factor a is required for kidney tubulogenesis in matrigel cultures in serum-free medium. Proc Natl Acad Sci USA, 87: 4002-4006, 1990.
5. Wilson MJ, Sinha AA: Human prostate tumor angiogenesis in nude mice: metallo-protease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells. Anat Record, 249: 63-73, 1997.
6. Benelli R, Albini A: In vitro models of angiogenesis: the use of Matrigel. Int J Biol Markers, 14: 243-246, 1999.
7. Kubota Y, Kleinman HK, Martin GR, Lawley TJ: Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol, 107: 1589-1598, 1988.
8. Albini A: Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res, 4: 230-241, 1998.
9. Farina AR, Tiberio A, Tacconelli A, Cappabianca L, Gulino A, Mackay AR: Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract. BioTechniques, 21: 904-909, 1996.
10. Mackay AR, Gomez DE, Cottam DW, Rees RC, Nason AM, Thorgeirsson UP: Identification of the 72-kDa (MMP-2) and 92-kDa (MMP-9) gelatinase/type IV collagenase in preparations of laminin and matrigel. BioTechniques, 15: 1048-1051, 1993.
11. Whittaker M, Ayscough A: Matrix metalloproteinases and their inhibitors - current status and future challenges. Cell Transmissions, 17: 3-14, 2001.
12. Manicourt DH, Lefebvre V: An assay for matrix metalloproteinases and other proteases acting on proteoglycans, casein, or gelatin. Anal Biochem, 215: 171-179, 1993.
13. Gallagher SR, Winston SE, Fuller SA, Hurrell JGR: Immunoblotting and immunodetection. In: Current protocols in molecular biology, vol 2, Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (Eds), pp 10.8.1, John Wiley & Sons, Inc, New Jersey, 1997.
14. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Abini A, Bologna M: Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer, 81: 395-403, 1999.
15. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res, 2: 1627-1636, 1996.
16. Delworth MG, Nishioka K, Pettaway CA, Gutman M, Killion JJ, von Eschenbach AC, Fidler IJ: Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol, 6: 293-299, 1995.
17. Stromqvist M, Andersson J-O, Bostrom S, Deinum J, Ehnebom J, Enquist K, Johansson T, Hansson L: Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1. Prot Exp Purification, 5: 309-316, 1994.
18. Sehgal I, Forbes K, Webb M: Reduced expression of MMPs, plasminogen activators and TIMPS in prostate cancer cells during repeated metastatic selection. Anticancer Res, 23: 39-42, 2003.
19. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem, 270: 5331-5338, 1995.
20. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, Cao J: Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem, 273: 1216-1222, 1998.
21. Product Manual for Western Lightning Chemiluminescence Reagent Plus, PerkinElmer Life Sciences, Inc, 549 Albany Street, Boston, MA, USA, copyright 2000.